|Traded as||Euronext: IPN|
CAC Mid 60 Component
|Marc de Garidel (Non-executive Chairman) David Meek (Chief Executive Officer)|
Number of employees
Ipsen has about 5,700 employees worldwide.
This article contains content that is written like an advertisement. (October 2018) (Learn how and when to remove this template message)
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €2.2 billion in 2018.
The Beaufour family, which ranks as the 42nd richest family in France, still owns 57% of its shares and 73% of its voting rights,:217 and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.[failed verification][failed verification]
The board of directors of Ipsen has appointed David Meek as chief executive officer, effective July 18, 2016. Former CEO Marc de Garidel assumes the role of non-executive chairman and continues to serve the board of directors through his deep industry expertise. In addition, Marc de Garidel will advise Mayroy, the Ipsen controlling holding company.
In 2018, Ipsen spent close to €302 million—13.5% of consolidated sales—on research and development.
in October 2016, European Commission approves Ipsen's Cabometyx (Cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.
The CABOSUN study, presented at the European Society for Medical Oncology (ESMO) 2016 congress, showed Cabometyx (Cabozantinib) can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma (RCC).
In November 2018, the European Commission (EC) approved Cabometyx (cabozantinib) 20, 40, 60 mg as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. This approval allows for the marketing of Cabometyx (cabozantinib) in this indication in all 28 member states of the European Union, Norway and Iceland.
In February 2019, Ipsen announced it would acquire Clementia Pharmaceuticals, a biopharmaceutical company specialized in rare bone diseases, for $1.3 billion. This acquisition is the largest in the history of Ipsen. In April 2019, Ipsen announced the deal was finalized.
Research and development
In 2018, Ipsen's R&D expenditure totaled close to €302 million, representing more than 13.5% of group sales.
Ipsen's main research and development centers are located in Cambridge (Massachusetts, United States), Milton Park / Oxford (United Kingdom) and Paris Saclay (France).
Board of directors
The board of directors sets the strategic guidelines for Ipsen's activities and oversees implementation.
- Marc de Garidel, chairman of the board of directors
- Anne Beaufour
- Henri Beaufour
- Philippe Bonhomme
- Antoine Flochel (vice-chairman).
- Margaret A. Liu
- David Meek
- Michèle OLLIER
- Paul Sekhri
- Carol Stuckley
- Piet Wigerinck
- Carol Xueref
Corporate executives are responsible for managing the group's operations and coordinating the group's various scientific, legal, financial, commercial and strategic actions.
- David Meek, CEO since July 2016.
- François Garnier, executive vice president, general counsel
- Benoît Hennion, executive vice president, consumer healthcare
- Dominique Laymand, executive vice president, chief ethics and compliance officer
- Dr Alexandre Lebeaut, executive vice president, research and development, chief scientific officer
- Aymeric Le Chatelier, executive vice president, chief financial officer
- Ivana Magovcevic-Liebisch, executive vice president, chief business officer
- Christopher Masterson, senior vice-president, quality
- Régis Mulot, executive vice president, chief human resources officer
- Aidan Murphy, executive vice president, technical operations
- Richard Paulson, executive vice president, chief executive officer in Ipsen North America
- Harout Semerjian, executive vice president, chief commercial officer
- Christian Marcoux, senior vice president, global communications
- Heather White, vice president, global internal audit
In 1983, Ipsen founded the Ipsen Foundation (Fondation Ipsen) with the help of the Fondation de France to track progress in biomedical research. It is headquartered in Boulogne-Billancourt. It has organised 64 colloquia, and it has partnered with the World Health Organization, the Fondation Nationale de Gérontologie, Harvard University, the Salk Institute for Biological Studies, the Massachusetts General Hospital, and the academic journals Nature and Cell.
- "Profile & key figures". Ipsen. Archived from the original on 1 February 2013.[self-published source]
- 2015 Registration Document (PDF) (Report). 29 March 2016. Archived from the original (PDF) on 4 June 2016.[self-published source]
- Challenges wealth ranking. Challenges.fr.
- Challenges. Challenges.fr. (internet archive > https://web.archive.org/web/20160602202417/http://www.challenges.fr/classements/fortune/fiche/famille-beaufour;44.html )
- Board of Directors Archived 1 February 2013 at the Wayback Machine. Ipsen.com.
-  Marc de Garidel, non-executive chairman
-  David Meek appointed CEO Ipsen
-  Marc de Garidel q2 2016 result earnings call transcript
- "Ipsen Gains Option to Buy Canbex Therapeutics for $6.8M+". 24 February 2015.
-  European Commission approves Ipsen’s Cabometyx for treatment of advanced renal cell carcinoma
-  Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx
- "Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3..." 25 February 2019 – via uk.reuters.com.
- "Ipsen completes acquisition of Clementia Pharmaceuticals". 18 April 2019 – via Pharmacy Business.
- Fondation Ipsen Archived 1 February 2013 at the Wayback Machine. Ipsen.com.
- (in French) Fondation de France. Fondation de France.